title: Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus.
abstract: Type 2 diabetes mellitus is a prevalent disease in Westernised society, and more than 50% of individuals with diabetes mellitus die from cardiovascular causes. The underlying metabolic defect of type 2 diabetes mellitus is a combination of insulin resistance and decreased secretion of insulin by pancreatic beta-cells. Insulin resistance commonly precedes the onset of type 2 diabetes mellitus and is usually associated with a metabolic syndrome including hypertension, dyslipidaemia and obesity. Treatment of known cardiovascular risk factors, including hyperglycaemia, dyslipidaemia, hypertension and smoking, plays a key role in delaying the onset and progression of coronary heart disease (CHD) and other forms of atherosclerosis in patients with diabetes mellitus. Sulphonylureas should be used with caution in patients with CHD but aspirin (acetylsalicylic acid), beta-blockers and ACE inhibitors play an important role in the medical management of patients with established coronary artery disease and diabetes mellitus. Patients with diabetes mellitus represent a higher risk group of patients after both percutaneous and surgical coronary revascularisation and the decision regarding the choice of revascularisation procedure should take into account angiographic characteristics, clinical status and patient preference. Patients presenting with diabetes mellitus and acute myocardial infarction should be considered for reperfusion therapy with either urgent thrombolytic therapy or primary percutaneous coronary intervention.
authors.affiliation: Division of Cardiovascular Diseases and Endocrinology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
authors.forename: S H
authors.initials: SH
authors.lastname: Wilson
authors.forename: F P
authors.initials: FP
authors.lastname: Kennedy
authors.forename: K N
authors.initials: KN
authors.lastname: Garratt
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000628:therapy*; D004032:Diet; D015444:Exercise; D006801:Humans; D006943:Hyperglycemia / Q000628:therapy; D006949:Hyperlipidemias / Q000628:therapy; D006973:Hypertension / Q000628:therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000628:therapy; D009204:Myocardial Revascularization
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007004:Hypoglycemic Agents